A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Colorectal Cancer, Skin Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 3/7/2019 |
| Start Date: | March 5, 2007 |
| End Date: | February 28, 2020 |
A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols
This study is intended to provide access to CP-675,206 for patients who have previously
received CP-675,206 in a clinical trial.
received CP-675,206 in a clinical trial.
Inclusion Criteria:
- The subject must have already received CP-675,206 in another protocol
- Females of childbearing potential must agree to practice a form of effective
contraception for 12 months following any dose of study drug. The definition of
effective contraception will be based on the judgement of the investigator.
- Subject must be willing and able to provide written informed consent and to comply
with scheduled visits and other trial procedures
Exclusion Criteria:
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials